First Line Metastatic Breast Cancer Treatment (ESMERALDA)
NCT ID: NCT01941407
Last Updated: 2016-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
61 participants
INTERVENTIONAL
2013-11-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
NCT01908101
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
NCT01663727
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
NCT00846027
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
NCT00391092
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
NCT00333775
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Association eribulin and bevacizumab
Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
Eribulin
Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eribulin
Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with metastatic mammary adenocarcinoma
* Hormone receptors ER and PR positive or negative for HER 2 negative
Exclusion Criteria
* Previous treatment with eribulin or bevacizumab
* Presence of symptomatic brain metastases or meningeal
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Claire HARDY-BESSARD, MD
Role: PRINCIPAL_INVESTIGATOR
Clinique Armoricaine de Radiologie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Paul Papin
Angers, , France
Centre Hospitalier d'Auxerre
Auxerre, , France
Institut Ste Catherine
Avignon, , France
Clinique Tivoli
Bordeaux, , France
Hôpital Fleyriat
Bourg-en-Bresse, , France
Hôpital Morvan - Centre Hospitalier Universitaire
Brest, , France
centre Francois baclesse
Caen, , France
Hôpital Privé Sainte-Marie
Chalon-sur-Saône, , France
Centre Hospitalier William Morey
Chalon-sur-Saône, , France
Centre d'Oncologie et de Radiothérapie
Dijon, , France
Centre Hospitalier la Dracénie
Draguignan, , France
Centre Hospitalier Intercommunal
Fréjus, , France
Hôpital Privé Drôme Ardèche - Clinique Pasteur
Guilherand-Granges, , France
Clinique de la Sauvegarde
Lyon, , France
Centre Léon Bérard
Lyon, , France
Hôpital Privé Clairval
Marseille, , France
Hôpital de Mont-de-Marsan
Mont-de-Marsan, , France
Centre d'oncologie de Gentilly
Nancy, , France
Centre Catherine de Sienne
Nantes, , France
Centre Antoine Lacassagne
Nice, , France
Centre Hospitalier Régional
Orléans, , France
Institut Curie - Hopital Claudius Régaud
Paris, , France
Hôpital Cochin
Paris, , France
Groupe Hospitalier Saint-Joseph
Paris, , France
Centre Catalan d'Oncologie
Perpignan, , France
Centre Hospitalier Lyon-sud
Pierre-Bénite, , France
Centre Hospitalier de la Région d'Annecy
Pringy, , France
Clinique Courlancy
Reims, , France
Institut Jean Godinot
Reims, , France
Centre Henri Becquerel
Rouen, , France
Anne-Claire Hardy-Bessard, MD
Saint-Brieuc, , France
Clinique Armoricaine de Radiologie
Saint-Brieuc, , France
Centre Hospitalier Privé de Saint-Grégoire
Saint-Grégoire, , France
GHPSO - Site Senlis
Senlis, , France
Centre de Radiothérapie - Clinique Sainte-Anne
Strasbourg, , France
Centre Hospitalier de Thonon-les-Bains
Thonon-les-Bains, , France
Clinique Pasteur
Toulouse, , France
CHU Bretonneau
Tours, , France
Centre Hospitalier de Valence
Valence, , France
Centre Hospitalier Bretagne Atlantique
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GINECO-BR110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.